Tags : Singapore


Biocardia, CellProThera & SlngXpand Collaborates to Develop and Commercialize CD34+

  Shots: SlngXpand will conduct clinical studies of expanded in vitro expanded peripheral blood CD34+ stem cells, CellProThera will fund the clinical studies and to receive exclusive commercialization rights of Biocardia’s Helix Biotherapeutic Delivery System in Singapore Biocardia to get royalties on sales of product from CellProThera. The expanded CD34+ stem cells are processed by […]Read More